Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 7
Submit an article Journal homepage
314
Views
55
CrossRef citations to date
0
Altmetric
Research Article

Pleiotropic Signal Transduction Mediated by Human CD30: A Member of the Tumor Necrosis Factor Receptor (TNFR) Family

Christof Schneider Department of internal Medicine III, University of Ulm, Robert-Koch-Str. 8, D-89081, Ulm, Germany
&
Gabriele Hübinger Department of internal Medicine III, University of Ulm, Robert-Koch-Str. 8, D-89081, Ulm, Germany
Pages 1355-1366 | Published online: 01 Jul 2009

  • Schwab, U., Stein, H., Gerdes, J., Lemke, H., Kirchner, H., Schaadt, M. and Dieht, V. (1982) "Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells". Nature 299, 65-67.
  • Stein, H., Mason, D.Y., Gerdes, J., O'Connor, N., Wainscoal, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lemke, H., et al., (1985) "The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplaslic lymphoid tissue: evidence that Reed-Slernberg cells and histiocytic malignancies are derived from activated lymphoid cells". Blood 66, 848-858.
  • Dürkop, H., Latza, U., Hummel, M., Eitelbach, E, Seed, B. and Stein, H. (1992) "Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease". Cell 68, 421-427.
  • Smith, C.A., Farrah, T. and Goodwin, R.G. (1994) "The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death", Cell 76, 959-962.
  • Baker, S.J. and Reddy, E.P. (1996) 'Transducers of life and death: TNF receptor superfamily and associated proteins". Oncogene 12(1), 1-9, Review.
  • Baker, S.J. and Reddy, E.P. (1998) "Modulation of life and death by the TNF receptor superfamily". Oncogene 17(25), 3261-3270, Review.
  • Tartaglia, L.A., Ayres, T.M., Wong, G.H. and Goeddel, D.V. (1993) "A novel domain within the 55 Ed TNF receptor signals cell death". Cell 74(5), 845-853.
  • Ashkenazi, A. and Dixit, V.M. (1999) "Apoptosis control by death and decoy receptors". Curr. Opin. Cell Biol. 11(2), 255-260, Review.
  • Gedrich, R.W., Gilfillan, M.C., Duckett, C.S., Van Dongen, J.L. and Thompson. C.B. (1996) "CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins". J Biol. Chem. 271(22), 12852-12858.
  • Horie, R., Aizawa, S., Nagai, M., Ito, K., Higashihara, M., Ishida. T, lnoue, J. and Watanabe, T. (1998) "A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation". Int. lmmunol. 10(2), 203-210.
  • Frocse, P., Lemke, H., Gerdes, J., Havsteen, B., Schwarting, R., Hansen, H. and Stein. H. (1987) "Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines", J Immunol. 139(6), 2081-2087.
  • Nawrocki, J.F., Kirsten, E.S. and Fisher, R.I. (1988) "Biochemical and structural properties of a Hodgkin's disease-related membrane protein". J lmmunol. 141(2), 672-680.
  • Fonatsch, C. Latza, U., Dürlcop, H., Rieder, H. and Stein, H. (1992) "Assignment of the human CD30 (Ki-I) gene to Ip36". Genomics 14(3), 825-826.
  • Dürkop, H., Anagnostopoulos, I., Bulfone-Paus. S. and Stein, H. (1997) "Expression of several members of the TNF-ligand and receptor family on tonsillar lymphoid B cells", Br. J. Haematol 98(4), 863-868.
  • Gerdes, J., Schwaning, R. and Stein, H. (1986) "High proliferative activity of Reed Stemberg associated antigen Ki-I positive cells in normal lymphoid tissue", J. Clin. Pathol. 39(9), 993-997.
  • Pallesen, G. (1990) "The diagnostic significance of the CD30 (KiI) antigen". Histopathology 16(4), 409-413, Review.
  • Chiarle, R., Podda, A., Prolla, G., Gong, J., Thorbecke, G.J. and Inghirami, G. (1999) "CD30 in normal and neoplastic cells". Clin, Immunol. 90(2), 157 164, Review.
  • Bengtsson, A., Johansson, C., Linder, M.T., Hallden, G., van der Ploeg. I. and Scheynius. A. (1995) "Not only Th2 cells but also Th I and Th0 cells express CD30 after activation", J. Leukoc. Biol. 58(6), 683-689.
  • Schwarting, R., Gerdes, J., Durkop, H., Falini, B., Pileri, S. and Stein, H. (1989) "BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a fonnol-resistant epitope". Blood 74(5), 1678-1689.
  • Kraft, M.S., Henning, G., Fickenscher, H., Lengenfelder, D., Tschopp, J., FIeckenstein, B. and Meinl, E. (1998) "Herpesvirus saimiri transforms human T-cell clones to stable growth without inducing resistance to apoptosis", J Virol. 72(4), 3138-3145.
  • Dürkop, H., Foss, H.D., Eitelbach, F., Anagnostopoulos, 1., Latza, U., Pileri. S. and Stein. H. (2000) "Expression of the CD30 antigen in non-lymphoid tissues and cells". J. Pathol. 190(5), 613-618.
  • Cerutti, A., Schaffer, A., Shah, S., Zan, H., Liou. H.C., Goodwin. R.G. and Casali, P. (1998) "CD30 is a CD40-inducible molecule that negatively regulates CD40-switching in non-antigen-selected human B cells". Immunity 9(2), 247-256.
  • Ellis,T.M., Simms, P.E., Slivnick, D.J., Jack, H.M. and Fisher. R.I. (1993) "CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+T cells". J. Immunol. 151(5), 2380-2389.
  • Ezawa, H., Harigaya, K., Ishii, G., Nakajima, N. and Mikata. A. (1997) "12-O-leiradecanoylphorboI-13-acetate (TPA) downregulates expression of CD30 in erythroleukemia cell line K562". Hematol. Oncol. 15(3), 151-161.
  • Bengtsson, A., Scheynius, A. and Avila-Carino, J. (2000) "Crosslinking of CD30 on activated human Th clones enhances their cylokine production and downregulates the CD30 expression". Scand. J. Immunol. 52(6), 595-601.
  • Dürkop, H., Oberbarnscheidt, M., Larza, U., Bulfone-Paus, S., Hirsch, B., Pohl, T. Krause, H., Hummel, M. and Stein, H. (2000) "The restricted expression pattern of the Hodgkin's lymphomaassociated cytokinc receptor CD30 is regulated by a minimal promoter". J Pathol 192(2), 182-193.
  • Croager, E.J., Gout, A.M and Abraham, L.J. (2000) "Involvement of Spl and microsatellite repressor sequences in the transcriptional control of the human CD30 gene". Am. J. Pathol. 156(5), 1723-1731.
  • Pallesen, G. and Hamitton-Dutoit, S.J. (1988) "Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma". Am. J. Pathol. 133(3), 446-450.
  • Latza, U., Foss, H.D., Durkop, H., Eitelbach, F., Dieckmann. K.P., Loy, V., Unger, M., Pizzolo, G. and Stein, H. (1995) "CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule", Am. J. Pthol. 146(2), 463-471.
  • Jones, TJ., Coad, N.A., Muir, K.R., Parkes, S.E., Evans, C.D. and Mann, J.R. (1995) "Immunophenotypic analysis of childhood Burkitt's lymphoma in the West Midlands 1957-1986". J. Clin. Pathol. 48(1), 22-25.
  • Higgins, J.P. and Warnke, R.A. (1999) "CD30 expression is common in mediastinal large B-cell lymphoma". Am. J. Clin. Pathol. 112(2), 241-247.
  • Stein, H., Foss, H.D., Durkop, H., Marafioli, T, Delsol, G., Pulford, K., Pileri, S. and Falini, B. (2000) "CD30(+) anaplastic large cell lymphoma: a review of its histopathologic. genetic, and clinical features", Blood 96(12), 3681-3695.
  • Morris, S.W., Xue, L., Ma, Z. and Kinney, M.C. (2001) "ALK" CD30' Iymphomas: a distinct molecular genetic subtype of NonHodgkin's Lymphoma". Br. J. Haematol.,
  • Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chau. J.K., Cleary. M.L. and Delsol, G. (1994) "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group". Blood 85(5), 1361-1392. Review.
  • Falini, B., Pileri, S., Pizzolo, G., Durkop, H., Flenghi, I.,. Stirpe, F. Martelli, M.F. and Stein, H. (1995) "CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy". Blood 85(1), 1-14, Review.
  • Smith, C.A., Gruss, H.J., Davis, T., Anderson, D., Farrah, T. Baker, E., Sutherland, G.R., Brannan, C.L. Copeland, N.G., Jenkins, N.A., et al. (1993) "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology toTNF'. Cell 73(7), 1349-1360.
  • Armitage, R.J. (1994) "Tumor necrosis factor receptor superfamily members and their ligands". Curr. Opin. Immunol. 6(3), 407-413. Review.
  • Younes, A., Consoli, U., Zhao, S., Snell, V., Thomas, E., Grass. H.J., Cabanillas, K and Andreeff, M. (1996) "CD30 ligand is expressed on resting normal and malignant human B lymphocytes". Br. J. Haemntal. 93(3), 569-571.
  • Kraft, M.S., Henning, G., Fickenscher, H., Lengenfelder, D., Tschopp, J., FIeekenstein, B. and Meinl, E. (1998) "Herpesvirus saimiri transforms human T-cell clones to stable growth without inducing resistance to apoptosis", J. Virol. 72(4), 3138-3145.
  • Dürkop, H., Foss, H.D., Eitelbach, F., Anagnostopoulos, L. Latza, U., Pileri, S. and Stein, H. (2000) "Expression of the CD30 antigen in non-lymphoid tissues and cells". J. Pathol. 190(5), 613-618.
  • Cerutti, A., Schaffer, A., Shah, S., Zan, H., Liou, H.C., Goodwin. R.G. and Casali, P. (1998) "CD30 is a CD40-inducible molecule that negatively regulates CD40-switching in non-antigen-selected human B cells". Immunity 9(2), 247-256.
  • Ellis,T.M., Simms, P.E., Slivnick, D.J., Jack, H.M. and Fisher. R.I. (1993) "CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+T cells". J. Immunol. 151(5), 2380-2389.
  • Ezawa, H., Harigaya, K., Ishii, G., Nakajima, N. and Mikata, A. (1997) "12-O-leiradecanoylphorboI-13-ncetate (TPA) downregulates expression of CD30 in erythroleukemia cell line K562". Hematol. Oncol. 15(3), 151-161.
  • Bengtsson, A., Scheynius, A. and Avila-Carino. J. (2000) "Crosslinking of CD30 on activated human Th clones enhances their cylokine production and downregulates the CD30 expression". Scand. J. Immunol. 52(6), 595-601.
  • Dürkop, H., Oberbarnscheidt, M., Larza, U., Bulfone-Paus, S., Hirsch, B., Pohl, T. Krause, H., Hummel. M. and Stein. H. (2000) "The restricted expression pattern of the Hodgkin's lymphomaassociated cytokinc receptor CD30 is regulated by a minimal promoter". J. Pathol 192(2), 182-193.
  • Croager, E.J., Gout, A.M and Abraham, L.J. (2000) "Involvement of SpI and microsatellite represser sequences in the transcriptional control of the human CD30 gene". Am. J. Pathol. 156(5), 1723-1731.
  • Pallesen, G. and Hamitton-Dutoit, S.J. (1988) "Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma". Am. J. Pathol. 133(3), 446-450.
  • Lalza, U., Foss, H.D., Durkop, H., Eitelbach, F., Dieckmann, K.P., Loy, V., Unger, M., Pizzolo, G. and Stein, H. (1995) "CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule", Am. J. Pathol. 146(2), 463-471.
  • Jones, T.J., Coad, N.A., Muir, K.R., Parkes, S.E., Evans, CD. and Mann, J.R. (1995) "Immunophenotypic analysis of childhood Burkilt's lymphoma in the West Midlands 1957-1986". J. Clin. Pathol. 48(1), 22-25.
  • Higgins, J.P. and Warnke, R.A. (1999) "CD30 expression is common in mediastinal large B-cell lymphoma". Am. J. Clin. Pathol. 112(2), 241-247.
  • Stein, H., Foss, H.D., Durkop, H., Marafioli, T, Delsol, G., Pulford, K., Pileri, S. and Falini, B. (2000) "CD30(+) anaplastic large cell lymphoma: a review of its histopathologic. genetic, and clinical features", Blood 96(12), 3681-3695.
  • Morris, S.W., Xue, L., Ma, Z. and Kinney, M.C. (2001) "ALK-CD30' Iymphomas: a distinct molecular genetic subtype of NonHodgkin's Lymphoma". Br. J. Haematol.
  • Harris, N.L., Jaffe, E.S., Stein, H., Banks, P.M., Chau, J.K., Cleary. M.L. and Delsol, G. (1994) "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group". Blood 85(5), 1361-1392. Review.
  • Falirti, B., Pileri, S., Pizzolo, G., Durkop, H., Flenghi, L., Stirpe, F., Martelli, M.F. and Stein, H. (1995) "CD30 (Ki-I) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy". Blood 85(1), 1-14, Review.
  • Smith, C.A., Gruss, H.J., Davis, T., Anderson, D., Farrah, T. Baker, E., Sutherland, G.R., Brannan, C.L. Copeland, N.G., Jenkins, N.A., et al. (1993) "CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology toTNF'. Cell 73(7), 1349-1360.
  • Armitage, R.J. (1994) "Tumor necrosis factor receptor superfamily members and their ligands". Curr. Opin. Immunol. 6(3), 407-413. Review.
  • Younes, A., Consoli, U., Zhao, S., Snell, V., Thomas, E., Gruss, H.J., Cabanillas, F. and Andrceff, M. (1996) "CD30 ligand is expressed on resting normal and malignant human B lymphocytes". Br. J. Haematol. 93(3), 569-571.
  • Yuunes, A., Consoli, U., Snell, V., CIodi, K., Kliche, K.O., Palmer. J.L., Gruss, H.J., Armitage, R., Thomas, E.K., Cabanillas, F. and Andreeff, M. (1997) "CD30 ligand in lymphoma patients with CD30+ tumors". J. Clin. Oncol. 15(11), 3355-3362.
  • Gattei, V. Celetti, A., Cerrato, A., Degan, M., De lulüs, A., Rossi. F.M., Chiappetta, G., Consales, C., Improta, S., Zagonel, V. Aldinucci, D., Agosti, V., Santoro, M., Vecchio, G., Pinto, A. and Grieco, M. (1997) "Expression of the RET receptor tyrosine kinase and GDNFR-alpha in normal and Ieukemic human hematopoietic: cells and stromal cells of the bone marrow microenvironment". Blood 89(8), 2925-2937.
  • Hsu, P.L. and Hsu, S.M (2000) "Autocrine growth regulation of CD30 ligand inCD30-expressing Reed-Stemberg cells: distinction between Hodgkin's disease and anaplastic large cell lymphoma". Lab. Invest. 80, 1111-1119.
  • Josimovic-Alasevic, O., Dürkop, H., Schwarting, R., Backe, E., Stein, H. and Diamantstein, T. (1989) "Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo, I. Partial characterization of soluble Ki-1 amigen and detection of the antigen in cell culture supernatants and in serum by an enzymelinked immunosorbent assay", Eur. J. lmmuaol. 19, 157-162.
  • Hansen, H.P., Kisseleva, T. Kobarg, J, Horn-Lohrens, O., Havsteen, B. and Lemke, H. (1995) "A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines". Int. J. Cancer 63, 750-756.
  • Hansen, H.P., Dietrich, S., Kisseleva, T., Mokros, T., Mentlein, R., Lange, H.H., Murphy, G. and Lemke, H. (2000) "CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme". J. Immunol. 165, 6703-6709.
  • Gerli, R., Muscat, C. Bistoni, O., Falici, B., Tomassini, C., Agea. E., Tognellini, R., Biagini, P. and Bertotto, A. (1995) HIgh levels of the soluble form of CD30 molecule in rheumatoid arthritis (R A) are expression of CD30+ T cell involvement in the inflamed joints". Clin. Exp. Immunol. 102, 547-550.
  • Dummer, W., Brocker, E.B. and Bastian, B.C. (1997) "Elevated serum levels of soluble CD30 are associated with atopic dermatitis, but not with respiratory atopic disorders and allergic contact dermatitis". Br. J. Dermatol. 137, 137-185.
  • Giacomelli, R., Cipriani, P., Lattanzio, R., Di Franco, M., Locarno. M., Parzanese, I., Passacantando, A., Ciocci, A. and Tonietti, G. (1997) "Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease". Clin. Exp. lmmunol. 108, 42-46.
  • Iwagaki, H., Hizuta, A., Kohka, H., Kobashi, K., Nitta, Y. Isozaki. H., Takakura, N. and Tanaka, N. (1999) "Circulating levels of soluble CD30 and other markers in colorectal cancer patients". J. Med. 30, 111-121.
  • Katoh, N., Hirano, S., Suehiro, M., lkenaga, K., Yamashita, T., Sugawara, N. and Yasuno, H. (2000) "Soluble CD30 is more relevant to disease activity of atopic dermatitis than soluble CD26", Clin. Exp. Immunol. 121, 187-192.
  • Din, H., Yazawa, N., Kubo, M., Yamane, K., Sato, S., Fujimoto. M., Kikuchi, K., Sonia, Y. and Tamaki, K. (2000) "Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease". J. Rheumatol. 27, 698-702.
  • Gerli, R., Bistoni, O., Lunardi, C., Giacomelli, R., Tomassini, C., Biagini, P. and Pitzalis, C. (1999) "Soluble CD30 in early rheumatoid arthritis as a predictor of good response to second-line therapy". Rheumatology 38, 1282-1284.
  • Nagahama, M., Nomura, S., Katsura, K., Ozaki, Y. Yoshimura, C., Kagawa, H. and Fukuhara, S. (2000) "Serum levels of soluble CD30 in aulologous peripheral blood stem cell transplantation". J. Cancer Res. Clin. Oncol. 126, 101-106.
  • Fattovich, G., Vinante, F., Giustina, G., Morosato, L., Alberti, A., Ruol, A. and Pizzolo, G. (1996) "Serum levels of soluble CD30 in chronic hepatitis B virus infection". Clin. Exp. Immunol. 103, 105-110.
  • Foschi, F.G., Gramenzi, A., Caslelli, E., Cursaro, C., Pagani, S., Margotri, M., D'Errico, A., Andreonc, P., Slefanini, G.F. and Beraardi, M. (2000) "Soluble CD30 serum level in HCV-positive chronic active hepatitis: a surrogate marker of disease activity?". Cytokine 2, 815-818.
  • Pizzolo, G., Vinante, F, Nadali, G., Krampera, M., Morosato, L., Chilosi, M., Raiteri, R. and Sinicco, A (1997) "High scrum level of soluble CD30 in acute primary HlV 1 infection". Clin. Exp. lmmunol. 108, 251-253.
  • Pizzolo, G., Vinante, F., Morosato, L., Nadali, G., Chilost, M., Gandini, G., Sinicco, A., Raiteri, R., Semenzalo, G., Stein, H., et al. (1994) "High serum level of the soluble form of CD30 molecule in the early phase of HlV-1 infection as an independent predictor of progression to AIDS". AIDS 8, 741-745.
  • Rizzardi, G.P., Tambussi, G., Barcellini, W., Capiluppi, B., Clerici. E., Maestra, L.I., LiIIo, K, Pantaleu, G. and Laszzarin, A. (1997) "Soluble CD30. tumor necrosis factor (TNF)-alpha. and TNF receptors in primary HlV-2 infection: relationship with HTV-1. RNA. clinical outcome and early antiviral therapy". J. Biol. Regul. Homeost. Agents 11, 43-49.
  • Cause, A., Pohl, C., Tschiersch, A., Da Costa, L., Jung, W., Dichy, V., Hasenrlevr, D. and Pfreuudschub, M. (1991) "Clinical ignificanve of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease". Blood 77, 1983-1988.
  • Nadali, G., Vinante, F., Ambrosetti, A.,Todeschini, G., Veneri, D., Zanolti, R., Meneghini, V. Ricetli, M.M., Benedetti, F., Vassanelli. A., et al. (1994) "Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis". J. Clin. Oncol. 12, 793-797.
  • Nadali, G., Vinante, F. Stein, H., Todeschini, G., Tecchio, C., Morosato, L., Chilosi, M. Meneslrina, F., Kinney, M.C., Greer, J.P., et al. (1995) "Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma". J Clin. Oncol. 13, 1355-1360.
  • Nadali, G., Tavecchia, L., Zanolin, E., Bonfunle, V. Viviani, S., Camerini, K., Musto, P., Di Renzo, N., Carolenuio, M., Chilosi, M, Krampera, M. and Pizzolo, G. (1998) "Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome". Blond 91, 3011-3016.
  • Zinzani, P.L., Pileri, S., Bendandi, M., Buzzi, M., Sabattini, E., Ascani, S., Gherlinzoni, F., Magagnoli, M., Albertini, P. and Tura, S. (1998) "Clinical implications of serum levels of soluble CD30 in 70 adult anaplaslic large-cell lymphoma: patients". J. Clin. Oncol. 16, 1532-1537.
  • Rotbe, M., Wong, S.C., Henzel, W.J and Goeddel, D.V. (1994) "A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor". Cell 78(4), 681-692.
  • Arch, R.H., Gedrich, R.W. and Thompson, C.B. (1998) "Tumor necrosis factor receptor-associated factors (TRAFs)-a family of adapter proteins that regulates life and death". Genes Deu 12(18), 2821-2830, Review.
  • Park, Y.C., Burkill, V., Villa, A.R., Tong, L. and Wu, H. (1999) "Structural basis for self-association and receptor recognition of human TRAF2". Nature 398(6727), 533-538.
  • Pullen, S.S., Labadia, ME., Ingraham, R.H., McWhirter, S.M., Everdeen, D.S., Alber, T., Crute, J.J. and Kehry. M.R. (1999) "High-aflinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization". Biochemistry 38 (31),10168-10177.
  • McCanhy, J.V., Ni, J. and Dixit, V.M. (1998) "RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase", J. iol. Chem. 273(27), 16968-16975.
  • Hsu, H., Xiong, J. and Goeddel, D.V. (1995) 'The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation". Cell 81(4), 495-504
  • Woronicz, J.D., Gao, X., Cao, Z., Rothe, M. and Goeddel, D.V. (1997) "IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NlK". Science 278(5339), 866-869.
  • Ling, L., Cao, A., and Goeddel, D.V. (199R) "NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176''. Proc. Natl. Acad Sci. USA 95(7), 3792-3797.
  • Nakano, H., Shindo, M., Sakon, S., Nishinaka, S., Mihara, M., Yagita, H. and Okumura, K. (1998) "Differential regulation of IkappaB kinase alpha and beta by two upstream kinnses. NF-kappa B-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-J". Proc. Natl. Acad. Sci. USA 95(7), 3537-3542.
  • Rothe, M., Sanna, V., Dixit, V.M. and Goeddel, D.V. (1995) "TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40". Science 269(5229), 1424-1427.
  • Kaye, K.M., Devergne, O., Harada, J.N., Izumi, K.M., Yalamanchili, R., Kieff, E. and Mosialos, O. (1996) "Tumor necrosis factor receptor associated factor 2 is a mediator of NFkappa B activation by latent infection membrane protein 1. the Epstem-Barr virus transforming protein", Proc. Natl. Acad. Sci. USA 93(20), 11085-11090.
  • Lee, S.Y, Kaufman, D.R., Mora, A.L., Santana, A., Boothby, M. and Choi, Y. (1998) "Stimulus-dependent synergism of the antiapoptotic tumor necrosis factor receptor-associated factor 2 (TRAF2) and nuclear factor kappa B pathways". J. Exp. Med. 188 (7), 1381-1384.
  • Kawamata, S., Hori, T., Imura, A., Takaori-Kondo. A. and Uchiyama, T. (1998) "Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAH) 2- and TRAFS-medialed NF-kappa B activation". J Biol. Chem. 273(10), 5808-5814.
  • Lee, H.H., Dempsey, P.W., Parks, T.P., Zhu, X., Baltimore, D. and Cheng, G. (1999) "Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappa B activation and intercellular adhesion molecule-1 up-regulation", Proc. Natl. Acad. Sci. USA 96(4), 421-1426.
  • Tsukamoto, N., Kobayashi, N., Azuma, S., Yamamoto, T. and Inoue, J. (1999) "Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40". Proc. Natl. Acad. Sci. USA 96(4), 1234-1239.
  • Darnay, B.C., Ni, J., Moore, P.A. and Aggarwal, B.B. (1999) "Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif, J. Biol. Chem. 274(12), 7724-7731.
  • Caunt, C.J., Kiss-Toth, K., Carlotti, F., Chapman, R. and Qwamstrom, E.E. (2001) "Ras controls tumor necrosis factor receptor-associated factor (TRAF)6-dependent induction of nuclear factor-kappa b. Selective regulation through receptor signaling components". J. Biol. Chem. 276(9), 6280-6288.
  • Pomerantz, J.L. and Baltimore, D. (1999) "NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBKI. a novel IKK-related kinase", EMBO J. 18(23), 6694-6704.
  • Caipentier, I. and Beyaert, R. (1999) "TRAFI is a TNF inducible regulator of NF-kappa B activation", FEBS Lett. 460(2), 246-450.
  • Schwenzer, R., Siemienski, K., Lipiay, S., Schubert, G., Peters, N., Scheurich, P., Schmid, R.M. and Wajant, H. (1999) "The human tumor necrosis factor (TNF) receptor-associated factor I gene (TRAFI) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappa B and c-Jun N-terminal kinase". J Biol. Chem. 274(27), 19368-19374.
  • Lee, S.Y., Lee, SY and Choi, Y. (1997) 'TRAP-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediaied NF-kappaB activation", J. Exp. Med. 185(7), 1275-1285.
  • Song, H.Y. Rothe, M. and Goeddel, D.V. (1996) "The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappa B activation", Proc. Natl. Acad. Sci. USA 93(13), 6721-6725.
  • Jaaitela, M., Mourilzen, H., Elling, F. and Bastholm, L. (1996) "A20 zinc finger protein inhibits TNF and IL-l signaling". J. Immunol. 156(3), 1166-1173.
  • Rothe, M., Pan, M.G., Henzel, W.J., Ayres, T.M. and Goeddel. D.V. (1995) "The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis, proteins". Cell 83(7), 1243-1252.
  • Uren, A.G., Pakusch, M., Hawkins, C.J., Puls, K.L. and Vaux, D.L. (1996) "Cloning and expression of apoptosis inhibitory protein hornologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors", Proc. Natl. Acad. Sci. USA 93(10), 4974-4978.
  • Deveraux, Q.L. and Reed, J.C. (1999) "LAP family proteinssuppressors of apoptosis". Genes Deu 13(3), 239-252. Review.
  • Natoli, G., Coslanzo, A., Ianni, A., Templeton, D.J., Woodgeu, J.R., Balsano, C. and Levrero, M. (1997) "Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway". Science 275(5297), 200-203.
  • Reinhard, C., Shamoon, B., Shyamala, V and Williams, L.T. (1997) "Tumor necrosis factor alpha-induced activation of c-jun N-terminal kinase is mediated by TRAF2", EMBO J. 16(5), 1080-1092.
  • Dadgostar, H. and Cheng, G. (2000) "Membrane localization of TRAF 3 enables JNK activation". J. Biol. Chem. 275(4), 2539-2344.
  • Kashiwada, M., Shirakaia, Y. Inoue, J.I., Nakano, H., Okazaki, K. Okumura, K., Yamamoio, T., Nagaoka, H. and Takemori, T. (1998) "Tumor necrosis factor receptor-associated kinase (ERK) activity in CD40 signaling along a ras-independent pathway". J. Exp. Med. 87(2), 237-244.
  • Grammer, A.C., Swamek, J.L., McFarland, R.D., Miura, Y., Geppert, T. and Lipsky, P.E. (1998) 'TNF receptor-associated factor-3 signaling mediates activation of p38 and Jun N-terminal kinase. tytokine secretion, and Ig production following ligation of CEMO on human B cells". J. lmmunol. 161(3), 1183-1193.
  • Cannons, J.L., Choi, Y. and Watts, T.H. (2000) "Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response". J. lmmunol. 165(11), 6193-6204.
  • Hatioglou, A., Roussel, J., Bourgeade, M.F., Rogier, E., Madry. C., Inoue, J., Devergne, O. and Tsapis, A. (2000) "TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1. TRAF2. and TRAF3 and activates NF-kappa B. elk-1. c-Jun N-terminal kuia.se, and p38 mitogen-activated protein kinase", J. lmmunol. 165(3), 1322-1330.
  • Hoeftich, K.P., Yeh, W.C., Yao, Z., Mak, TW. and Woodgett, J.R. (1999) "Mediation of TNF receptor-associated factor effector functions by apoptosis signal-regulating kinase-1 (ASK1)". Oncogene 18(42), 5814-5820.
  • Lee, S.Y, Lee, S.Y., Kandala, G., Ltou, M.L., Liou, H.C. and Choi. Y (1996) "CD30/TNF receptor-associated factor interaction: NFkappa B activation and binding specificity". Proc. Natl. Acad. Sci. USA 93(18), 9699-9703.
  • Boucher, L.M., Marengere, L.E., Lu, Y. Thukral, S. and Mak, T.W. (1997) "Binding sites of cytoplasmic effectors TRAF1,2. and 3 on CD30 and other members of the TNF receptor superfamily", Biochem. Biophys. Res. Commun. 233(3), 592-600.
  • Ducken, C.S., Gedrich, R.W., Gilfillan, M.C. and Thompson, C.B. (1997) "Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2'. Mol. Cell. Biol. 17(3), 1535-1542.
  • Aizawa, S., Nakano, H., Ishida, T. Horie, R., Nagai, M., lto, K., Yagita, H., Okumura, K., tnoue, J. and Watanabe. T. (1997) "Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation", J. Biol. Chem. 272(4), 2042-2045.
  • Ishida, T. Mizushima, Si., Azuma, S., Kobayashi, N., Tojo, T. Suzuki, K., Aizawa, S.W., Mosialos, G., Kieff, E., Yamamoto, T. and Inoue, J. (1996) "Identification of TRAF6, a novel tumor necrosis factor receptor-associated protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region". J. Biol. Chem. 271(46), 28745-28748.
  • Tsitsikov, E.N., Wright, D.A. and Geha, R.S. (1997) "CD30 induction of human immunodeficiency virus gene transcription is mediated by TRAF2". Proc. Natl. Acad. Sd. USA 94(4), 1390-1395.
  • Pype, S., Declereq, W., Ibrahimi, A., Michiels, C., Van Rietschoten, J.G., Dewutf, N., de Vandenabeele, P., Huylehroeck. D. and Remacle, J.E. (2000) "TTRAP. a novel protein that associates with CD40, tumor necrosis factor receptor-75 and TNF receptor-associated factors (TRAFs). and that inhibits nuclear factor-kappa B activation". J Biol. Chum. 275(24), 18586-18593.
  • Mathew, P., Sanger, W.G., Weisenburger, D.D., Valentine, M., Valentine, V., Pickering, D., Higgins, C., Hess, M., Cui, X., Srivastava, D.K. and Morris, S.W. (1997) "Detection of the 1(2;5)(p23;q35) and NPM-ALK fusion in non-Hodgkin's Iymphoma by two-color fluorescence in situ hybridization". Blood 89(5), 1678-1685.
  • Morris, S.W., Kirstein, M.N., Valentine, MB., Dittmer, K.G., Shapiro, D.N., Sallman, D.L. and Look. A.T. (1994) "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM. in non-Hodgkin's Iymphoma". Science 263(5151), 1281-1284.
  • Pulford, K., Lamant, L., Morris, S.W., Butler, L.H., Wood, K.M., Stroud, D., Detsol, G. and Mason, D.Y (1997) "Detection of anaplastic Iymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALKI". Blood 89(4), 1394-1404.
  • Dreier, H.G., Gignac, S.M., von Wasielewski, R., Werner, M. and Dirks, W.G. (2000) "Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell Iymphoma and other lymphomas". Leukemia 14, 1533-1559.
  • Len Berge, R.L., Oudejans, J.J., Ossenkonpete, G.J., Pulford, K., Willemze, R., Falini, B., Chott, A. and Meijer, C.J. (2000) "ALK expression in extranodal anuplastic large cell Iymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination". J. Clin. Pathol. 53(6), 445-450.
  • Falini, B., Pileri, S., Zinzani, P.L., Carbone, A., Zagonel, V., WoIfPeeters, C., Verhoef, G., Monestrina, F., Todeschini, G., Paulli, M., Lazzarino, M., Giardini, R., Aiello, A., Foss, H.D., Araujo, I., Fizzoiti, M., Pelicci, P.G., Flenghi, L., Martelli, M.F. and Santucci. A. (1999) "ALK+ lymphoma: clinico-pathological findings and outcome", Blood 93(8), 2697-2706.
  • Shiola, M., Fujimoto, J., Semba, T., Satoh, H., Yamamoto, T. and Mori, S. (1994) "Hyperphosphorylation of a novel 80 kDa proteintyrosine kinase similar to Lik in a human Ki-1 lymphoma cell line. AMS3". Oncogene 9(6), 1567-1574.
  • Hübinger, G., Scheffrahn, L., Muller, E., Bai, R., Duysler, J., Morris, S.W., Schrezenmeier, H. and Bergmann, L. (1999) 'The tyrosine kinase NPM-ALK. associated with anaplastic large cell Iymphoma. binds the intraccllular domain of the surface receptor CD30 but is not activated by CD30 stimulation". Exp. Hematol. Dec; 27(12), 1796-1805.
  • Bischof, D., Pulford, K., Mason, D.Y. and Morris, S.W. (1997) "Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associaied NPM-anaplastic Iymphoma kinase fusion protein in oncogenesis", Mol. Cell. BM. 17(4), 2312-2325.
  • Bai, R.Y., Dieter, P., Peschel, C., Morris, S.W. and Duyster, J. (1998) "Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity". Mol. Cell. Biol. 18(12), 6951-6961.
  • McDonald, P.P., Cassalella, M.A., Bald, A., Maggi, E., Romagnani, S., Gruss, H.J. and Pizzolo, G. (1995) "CD30 ligalion induces nuclear factor-kappa B activation in human T cell lines", Eur. J. Immunol. 25(10), 2870-2876.
  • Jung, W., Krueger, S., Renner, C., Cause, A., Sahin, U., Tromper. L. and Pfreundschuh, M. (1994) "Opposite effects of the CD30 ligand are not due to CD30 mutations: results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Mol. Immunol. 31(17), 1329-1334.
  • Lee, S.V. Park, C.G. and Choi, Y. (1996) "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors", J Exp. Med. 183(2), 669-674.
  • Telford, W.G., Nam, S.Y., Podack, E.R. and Miller, R.A. (1997) "CD30-regulaled apoptosis in murine CDS T cells after cessation of TCR signals". Cell Immunol. 182(2), 125-136.
  • Amakawa, R., Hakem, A., Kundig, T.M., Matsuyania, T., Simard. J.J., Timms, K., Wakeham. A., Mittruecker, H.W., Griesser, H., Takimoto, H., Schmits, R., Shahinian, A., Ohashi, P., Penninger. J.M. and Mak, T.W. (1996) "Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice". Cell 84(4), 551-562.
  • Chiarle, R., Podda, A., Prolla, G., Podack, E.R., Thorbecke, G.J. and lnghirami, G. (1999) "CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bel-2-sensitive pathway", J. Immunol. 163(1), 194-205.
  • DeYoung, A.L., Duramad, O. and Winoto, A. (2000) "The TNF receptor family member CD30 is not essential for negative selection". J. Iminunol. 165(11), 6170-6173.
  • Ducken, C.S. and Thompson. C.B. (1997) "CD30-dependent degradation of TRAH2: implications for negative regulation of TRAF signaling and the control of cell survival". Genes Dev 11(21), 2810-2821.
  • Tran, Z.G., Longo, D.L. Funakoshi, S., Asai, O., Penis, D.K., Widmer, M. and Murphy, W.J. (1995) "In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts". Cancer Res. 55(22), 5335-5341.
  • Pfeifer, W., Levi, E., Petrogiannis-Haliotis, T., Lehmann, L., Wang, Z. and Kadin, M.E. (1999) "A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1)", Am. J. Pathol. 155(4), 1353-1359.
  • Mori, M., Manuelli, C., Pimpinelli, N., Mavilia, C., Maggi, E., Saniucci, M., Bianchi, B., Cappugi, P., Uiannotli, B. and Kadin. M.E. (1999) "CD30-CD30 ligand interaction in primary cutaneous CD30(+) T-cell lymphomas: a clue to the pathophysiology of clinical regression". Blood 94(9), 3077-3083.
  • Hubinger, G., Müller. E., Scheider, C., Schneider, C., Hildlt. C., Singer, B.B., Sigg, L., Graf, S. and Bergmann. L. (2001) "CD30-mediated cell cycle arrest associated with induced expression of p21 C1P1/WAF1 in the anaplastic large cell lymphoma cell line Karpas 299". Oncogene 20, 590-598.
  • Grell, M., Zimmermann, G., Gottfried, E., Chen, C.M., Grunwald. U., Huang, D.C., Wu Lee, Y.H., Durkop, H., Engelmann, H., Scheunen, P., Wajant H. and Strasser, A. (1999) "Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membraneanchored TNF'. EMBO J. 18(11), 3034-3043.
  • Mir. S.S., Richter, B.W. and Ducken, C.S. (2000) "Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells". Blood 96(13), 4307-4312.
  • Muta, H., Boise, L.H., Fang, L. and Podack, K.R. (2000) "CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis". J. Immunol. 165(9), 5105-5111.
  • Levi, E., Wang, Z., Petrogiannis-Haliotis, T., Pfeifer, W.M., Kempf, W., Drews, R. and Kadin, M.E. (2000) "Distinct effects of CD30 and Fas signaling in cutaneous anaplastic lymphomas: a possible mechanism for disease progression". J. Invest. Dermatol. 115(6), 1034-1040.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.